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Summary  
 
ADHD is a childhood-onset neurodevelopmental disorder with a prevalence of 1.4%- 
3%. It is more common in boys. Comorbidity with childhood-onset 
neurodevelopmental disorders and psychiatric disorders is substantial. ADHD is 
highly heritable and   multifactorial; multiple genes and non-inherited factors 
contribute. Pre-/perinatal factors have been implicated as risks, but definite causes  
remain unknown.  Most guidelines recommend a stepwise approach to treatment, 
beginning with non-drug interventions and then moving to medication in those most 
severely affected. Randomised controlled trials show short term benefits of 
stimulant medication and atomoxetine. Meta-analyses of blinded non-drug 
treatment trials have not yet proven their efficacy. Longitudinal studies of ADHD 
show heightened risk of multiple mental health and social difficulties as well as 
premature mortality in adult life.  
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Second summary 
 
ADHD is a common neurodevelopmental disorder characterised by developmentally 
inappropriate and impairing levels of inattention, hyperactivity and impulsivity 
across different settings. It presents in childhood and is more common in males than 
females. Its prevalence in the general population is 3.4%. 
 
ADHD is diagnosed according to strictly defined criteria – despite extensive 
investigation into its pathophysiology there is as yet no diagnostic biological test. 
Although the ICD-10 and DSM-5 provide defined diagnostic thresholds, clinical 
features of ADHD behave as a continuously distributed risk dimension, meaning it is 
important to be mindful that sub-threshold ADHD symptoms, although not an 
indication for treatment, do carry risk. 
 
The clinical presentation of ADHD varies considerably between individuals. Early 
comorbidity with developmental, learning and psychiatric problems is common. 
Whether ADHD itself persists into adulthood is variable – whilst many will continue 
to meet full diagnostic criteria or have sub-threshold symptoms, some will 
experience symptom remission but continue to have different types of difficulties.  
ADHD is a risk factor for later adverse outcomes such as poor educational 
attainment, social difficulties, substance misuse and criminality.  
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The causes of ADHD are complex and multifactorial, with genetics, early 
environment and gene-environment interplay all being involved. No single risk factor 
is either necessary or sufficient to explain its occurrence. ADHD is highly heritable, 
and multiple types of genetic variants appear to be involved. None are diagnostic. 
Early environmental factors (e.g. diet, pre- and perinatal factors, toxins and 
psychosocial risks) have also been extensively investigated but whilst correlations 
have been found between many environmental influences and ADHD, it is difficult to 
prove definite causes.  Later, potentially modifiable factors might influence its course 
and outcomes and more research is needed on this. 
 
Clinical assessment should be detailed and go beyond asking about diagnostic items. 
There are specific guidelines for the stepwise management of ADHD, and when 
following these, the severity of symptoms and an individual’s circumstances and 
medical history should be taken into account. If ADHD medications are prescribed, it 
should be in conjunction with behavioural interventions. ADHD medication needs to 
be regularly reviewed. 
 
ADHD in many respects behaves like a chronic medical disorder. For many 
individuals, multimodal interventions that are carefully adjusted over time will be 
important. A developmental approach to assessment and treatment is necessary, 
taking into account how presentation and risks change over time.  
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Introduction 
 
Attention deficit hyperactivity disorder (ADHD) is a childhood-onset 
neurodevelopmental disorder characterised by developmentally inappropriate and 
impairing inattention, motor hyperactivity, and impulsivity with difficulties often 
continuing into adulthood. In this seminar we aim to update and inform early career 
clinicians on issues relevant to clinical practice and discuss some controversies and 
misunderstandings.  
 
Defining attention deficit hyperactivity disorder 
 
 
ADHD is a diagnostic category in the American Psychiatric Association’s Diagnostic 
and Statistical Manual (DSM-IV)1 and the more recent DSM-5.2 The broadly 
equivalent diagnosis used predominantly in Europe is hyperkinetic disorder which is 
defined in the World Health Organisation’s International Classification of Diseases 
(ICD-103). This definition captures a more severely affected group of individuals, as 
reported prevalence rates for hyperkinetic disorder are lower than for DSM-IV ADHD 
even within the same population.4 Table 1 provides a description of the key 
diagnostic criteria. DSM-5 now has longer symptom descriptors which also capture 
how symptoms may manifest in older adolescents and adults. DSM-IV distinguished 
inattentive, hyperactive-impulsive and combined subtypes of ADHD, with the 
combined type requiring symptoms across the domains of inattention and 
hyperactivity-impulsivity. However, ADHD subtypes are not stable across time5 and 
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DSM-5 has de-emphasised their distinctions. ICD-10 does not distinguish subtypes; 
symptoms are required in the three separate domains of inattention, hyperactivity, 
and impulsivity for a diagnosis of hyperkinetic disorder. 
 
The diagnosis of ADHD or hyperkinetic disorder also requires the presence of 
symptoms across more than one setting (e.g. home and school) and requires that the 
symptoms needed for diagnosis result in impairment, for example in academic, social 
or occupational functioning. Onset must be early although DSM-5 has changed the 
age of onset from before age 7 (ICD-10 and DSM-IV) to before age 12 years.  
 
Like all complex medical and psychiatric disorders, ADHD shows marked 
heterogeneity at clinical, aetiological and pathophysiological levels. Individuals with 
a diagnosis of ADHD differ from each other in terms of their core symptom 
combinations, level of impairment and comorbidities as well as on other background 
individual, family and social factors. 
 
For clinical purposes, defining ADHD categorically is useful given that clinical 
decisions tend to be categorical in nature – e.g. whether to refer to specialist 
services or to treat. However, like many medical conditions (such as hypertension 
and diabetes), in terms of aetiology and outcomes as discussed later, ADHD may also 
be viewed as a continuously distributed risk dimension. In common with other 
continuously distributed phenotypes (e.g. blood pressure) it could be argued that 
there is a lack of objective cut-point that defines the diagnostic threshold. Indeed, 
those who have “sub-threshold” symptoms are also at heightened risk of adverse 
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outcomes6 (as it is for hypertension). However, ultimately categorical decisions on 
resource allocation and treatment have to be made, and ICD- or DSM-defined 
diagnosis provides a reliable way of balancing the risks and benefits of giving 
someone a diagnostic label and providing treatments that are not free of adverse 
effects. A further challenge which is the case for all psychiatric disorders and some 
neurological conditions (e.g. migraine), comes from diagnosis being based on 
reported symptoms alone, there are no biological tests. This means that even with 
clear-cut diagnostic criteria, there is potential risk of over- and under-diagnosis and 
this underscores the importance of careful and rigorous expert assessment.7 
Concerns about under- and over-diagnosis are not restricted to ADHD or psychiatric 
conditions.8   
 
Epidemiology 
 
In the general population, the estimated prevalence of ADHD in children is 3.4% (CI 
95% 2.6-4.5) according to the most recent meta-analysis9 with lower rates of around 
1.4% reported for hyperkinetic disorder from European studies.10 International 
comparisons show that the prevalence does not vary by geographical location but is 
affected by heterogeneity in assessment methods (e.g. using an additional informant 
to parent) and diagnostic conventions (e.g. ICD vs. DSM).11 It is worth highlighting 
that there is a marked under-representation of ADHD studies from low- and middle-
income countries. 
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One common assumption is that ADHD must be a modern phenomenon. However, a 
case series of children presenting with the characteristic clinical features was 
published by the British paediatrician Sir George Still in The Lancet in 190212 and 
there are descriptions that predate this publication by several centuries. Time trends 
studies of non-referred population cohorts in the later 20th and early 21st centuries 
find no evidence of a rise in rates of ADHD symptoms or diagnosis across time.13,14  
However, there has been a very marked rise in the number of prescriptions issued 
for ADHD medications across high-income countries in the last decade.15,16,17 Rises in 
clinic incidence and treatment could simply indicate increased parent and teacher 
awareness of ADHD and/or changes in impact.18,19 Nevertheless, European studies 
have repeatedly found that despite the rise in ADHD treatment, the administrative 
prevalence is lower than the population figure, highlighting that in these countries 
there is still under-diagnosis.17,20,21 However, in the United States, similar types of 
studies show geographical variation in patterns of under- and over-diagnosis/ADHD 
medication prescribing.22,23 Such findings highlight there is the potential for 
misdiagnosis and inappropriate medication use if safeguards are not in place. These 
include ensuring full, good quality clinical assessments are undertaken although 
these require time and adhering to national and international treatment guidelines. 
However there is no evidence of rising population levels of ADHD explained by social 
change contrary to belief by some.  
  
An excess of affected males is a strongly consistent epidemiological finding, although 
the male:female ratio of 3-4:1 found in epidemiological samples is increased in clinic 
populations to around 7-8:1 suggesting referral bias in relation to females with 
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ADHD.24 The same male preponderance is observed for other neurodevelopmental 
disorders such as autism spectrum disorder, intellectual disability (IQ<70) and 
communication disorders.25 
 
The natural history of ADHD is best observed in prospective longitudinal studies. As 
is typical of neurodevelopmental disorders, its core defining features tend to decline 
with age, although inattentive features are more likely to persist. However, in line 
with its heterogeneous clinical presentation, the developmental trajectories of ADHD 
are highly variable - whilst around 65% continue to meet full criteria or have only 
achieved partial remission by adulthood, some do experience full remission.26 
Although good quality, large epidemiological studies of the prevalence of ADHD in 
adulthood are lacking, one meta-analysis of adult ADHD yielded a pooled prevalence 
rate of 2.5% (95% CI 2.1-3.1).27 However, there are still uncertainties as to what 
constitutes the optimal way of defining ADHD (or indeed any neurodevelopmental 
disorder) in adulthood. The recently published DSM-52 explicitly allows for symptom 
decline and requires a reduced symptom number for adult ADHD. In clinical settings, 
diagnosing ADHD in adults who did not present in childhood requires some caution 
as it is challenging for young adults and those who know them to retrospectively 
date symptom onset in the absence of documented information.28 Objective records 
(e.g. school reports) could help in this regard. Despite these caveats, there is 
certainly sufficient evidence (see also prognosis) to conclude that ADHD is not simply 
a problem that most children “grow out of”. However transitioning from child to 
adult mental health clinics is a problem due to a lack of adult services.29   
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Early comorbidity 
 
ADHD shows high concurrent comorbidity with other neurodevelopmental disorders; 
namely autism spectrum disorder, communication and specific learning or motor 
disorders (e.g. reading disability, developmental co-ordination disorder), intellectual 
disability and tic disorders.30,31,32 Unsurprisingly, rates of comorbidity are higher in 
those who are referred.33 ADHD also shows high concurrent comorbidity with 
behaviour problems, namely oppositional defiant and conduct disorders.31,34 
Children with ADHD and conduct disorder show greater neurocognitive impairment 
and a worse prognosis35,36 and this subgroup of children with hyperkinetic conduct 
disorder is distinguished in ICD-10 but not in DSM-5. Comorbidity with psychiatric 
disorders that typically have onset after puberty is discussed later. 
 
Risk factors 
 
As for all complex disorders, no single risk factor is either necessary or sufficient to 
explain ADHD – multiple genetic and non-genetic/environmental factors contribute 
to risk and the pattern of inheritance is multifactorial for the majority of affected 
individuals.  
 
Genetics 
ADHD is a familial disorder. Its relative risk is around 5-9 in first degree relatives of 
probands with ADHD.37 Numerous twin studies of ADHD from different countries 
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consistently yield very high heritability estimates of around 76%, a magnitude similar 
to that observed for schizophrenia and autism.38  
 
The genetic architecture of ADHD is similar to other neuropsychiatric disorders such 
as schizophrenia. Several different classes of genomic variants39 have been found to 
be associated with ADHD risk. These include common (defined as >5% population 
frequency) DNA sequence variants called single nucleotide polymorphisms (SNPs), 
but associations have only been observed when thousands are combined into a 
composite genetic risk score.40 Subtle chromosomal mutations involving rare 
(defined as <1% frequency) deletions and duplications called copy number variants 
(CNVs) are also associated with ADHD risk.41 These have larger effect sizes but are 
uncommon.  
 
Prior to whole genome investigations, certain single dopaminergic, serotonergic and 
noradrenergic candidate genes stood up to meta-analyses.42,43 However in the 
present era of whole-genome investigation, psychiatric candidate gene studies of 
DNA variants in single genes are viewed with caution because of the potential for 
false positives.44 
 
ADHD-associated genomic variants are non-specific; composite genetic risk scores  
show significant overlap with those contributing to schizophrenia and mood 
disorders.45,46 ADHD-associated CNVs also show overlap with ones associated with 
schizophrenia, autism and intellectual disability.41,47 Although testing for rare CNVs is 
recommended now for those with intellectual disability, this is not the case for 
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ADHD.  Ascertaining causality requires further and different types of investigation 
(see 39 for details).  
 
Whilst the majority of ADHD is multi-factorial in origin, there are a number of known, 
rare genetic syndromes (such as fragile X syndrome, tuberous sclerosis, 22q11 
microdeletion and Williams syndrome) characterised by higher rates of ADHD and 
ADHD-like features. These syndromes are also associated with higher risk of other 
disorders, such as autism (especially in fragile X syndrome and tuberous sclerosis) 
and schizophrenia (22q11 microdeletion syndrome). In typical clinic populations with 
ADHD, there is no evidence to suggest that routine screening for these genetic 
syndromes is warranted in the absence of intellectual disability.48  
 
Environment and gene-environment interplay 
Environmental factors also are known to be important in ADHD. As evidence on 
modifiable causes impacts on clinical decision making, public health priorities and 
clinician and patient behaviour49 we will discuss whether findings on individual 
environmental risks meet accepted standards for inferring causation.50  
 
Observational case-control and epidemiological studies show that exposures to a 
variety of pre-and perinatal factors, environmental toxins, dietary factors and 
psychosocial factors are all associated with ADHD.38 If causal, that would mean 
manipulating the risk factor alters the outcome. However, association does not 
mean causation because exposures to risks are not randomly allocated and can be 
influenced by unmeasured confounders, selection factors and reverse causation 
13 
 
whereby the phenotype influences the environmental exposure. It is with these 
caveats in mind that evidence for environmental causation must be interpreted.   
 
Pre-and perinatal factors observed to be associated with ADHD include  low birth 
weight and prematurity51 and in utero exposure to maternal stress, cigarette 
smoking, alcohol, prescribed drugs (e.g. acetaminophen/paracetamol) and illicit 
substances.38,52,53 In relation to prenatal smoking and stress, quasi-experimental 
designs suggest most or all of the association with offspring ADHD, unlike with 
offspring birth weight, is explained by unmeasured confounds.54,55,56,57,58  
 
Environmental toxins, specifically in utero or early childhood exposure to lead, 
organophosphate pesticides and polychlorinated biphenyls are risk factors (see 
detailed review in38). Nutritional deficiencies (e.g. zinc, magnesium and 
polyunsaturated fatty acids), nutritional surpluses (e.g. sugar and artificial food 
colourings) and low/high IgG food have not been found to convincingly precede 
ADHD and at present should be regarded as correlates.  Effective treatments for any 
disorder, unlike prevention, do not necessarily have to deal with its causes or origins 
(see later). 
 
Psychosocial risks, such as low income, family adversity and harsh/hostile parenting, 
whilst robustly causal for certain psychiatric disorders, are also correlates rather 
than proven causes of ADHD. Longitudinal studies,59 treatment trials60 and a study of 
children adopted away at birth61 suggest that observed negative mother-child 
relationships (even in unrelated mothers) arise as a consequence of early child ADHD 
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symptoms (reverse causation) and improve with treatment. However, exposure to 
very severe, early social deprivation appears to be different and causal. After being 
adopted away in the UK, Romanian orphans reared in institutions and exposed to 
extreme early privation in the first year of life showed elevated rates of ADHD-like 
features, cognitive difficulties and quasi-autistic features that persisted to 
adolescence.62,63 Psychosocial context may well shape ADHD presentations and alter 
developmental trajectories, outcomes and impairments - but surprisingly this has 
been not been investigated widely (see Figure 1 on origins vs. trajectories). 
Regardless of what causes ADHD,  treatment is based on clinical features not 
assumed aetiology. 
 
As a final word on risk factors, many mistakenly assume that the action of genes (or 
biology) and environment are distinct, which is incorrect. Potentially important 
environmental risks for ADHD and its outcomes may be brought about as a 
consequence of genetic propensities (gene-environmental correlation; e.g.61). Their 
effects on clinical phenotype may also depend on genetic liability. For example, 
animal studies have robustly shown experimentally that environment can alter 
behaviour in different ways depending on the variant of gene carried (gene-
environment interaction39). Gene-environment interplay effects are subsumed in 
twin heritability estimates. Finally, there is very good evidence that environmental 
exposures result in biological changes49 including ones involving brain structure, 
function and altered DNA methylation (epigenetics). This highlights that genes, 
environment and biology work together. However in humans, these issues are 
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complex -  they will not be discussed in detail here, but have been reviewed 
elsewhere.38,39,49  
 
Pathophysiology 
 
 
Biology 
The biological mechanisms through which genetic and environmental influences act 
and interact to alter neurodevelopment in ADHD are not yet understood and there 
remains no diagnostic neurobiological marker. The validity of animal models of 
ADHD are currently limited by our incomplete understanding of its pathophysiology 
in humans and the extent to how well inattention, motor over-activity, and impulsive 
responses on behavioural tasks in non-human species represent ADHD.64 However 
they have suggested involvement of dopaminergic and noradrenergic 
neurotransmission (in line with the neurochemical effects of ADHD medications) as 
well as of serotonergic neurotransmission. 65 
 
Cognition 
Whilst there is no cognitive profile which defines ADHD, deficits in various 
neuropsychological domains have been reliably identified. In terms of executive 
functioning, the most consistent and strong associations are seen for response 
inhibition, vigilance, working memory, and planning.66 In terms of non-executive 
deficits, associations are seen with timing,67 storage aspects of memory,68 reaction 
time variability69 and decision making.70 However, there is considerable 
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heterogeneity in cognitive functioning even within single samples,71 and there is not 
a straightforward association between cognitive performance and the trajectory of 
clinical symptoms.72,73 There is evidence though that some cognitive deficits are 
improved by methylphenidate, with a meta-analysis of its effect finding 
improvements in executive and non-executive memory, reaction time, reaction time 
variability and response inhibition.74  
 
Imaging 
Functional magnetic resonance imaging (fMRI) studies have found abnormalities in 
the function of many neural networks in response to cognitive tasks. A meta-analysis 
of task-based fMRI studies has identified alterations in several networks including 
those related to attention and executive function.75 In terms of brain structure, a 
meta-analysis of structural MRI studies highlights alterations in the basal ganglia and 
limbic areas.76 A meta-analysis of diffusion MRI studies, which investigate white 
matter microstructure, finds alterations to be widespread, but mostly reliably seen in 
the right anterior corona radiata, right forceps minor, bilateral internal capsule and 
left cerebellum.77 Reduced total grey matter and altered basal ganglia volumes 
appear to index familial risk for ADHD.78 The literature is increasingly suggesting that 
the pathophysiology of ADHD involves abnormal interactions between large-scale 
brain networks, however current imaging studies do not yet have relevance to 
clinical practice.79 Interpretation is complex due to many factors, including the cross-
sectional nature of most studies: longitudinal data regarding the trajectory of cortical 
development suggest that the brain may show maturational delay, with persistence 
of ADHD indexed by progressive divergence from the normal trajectory80 but it is not 
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yet known whether this phenomenon can be extrapolated to other metrics of 
structure, microstructure and function. The effect of medication is also a 
consideration as there is some evidence to suggest it appears to normalise 
macrostructure and function.81 Nonetheless, there is some evidence from 
longitudinal  studies of adults with childhood ADHD that grey and white matter 
abnormalities persist well into adulthood.82,83  
 
Clinical assessment 
 
The ADHD assessment process requires careful clinical history taking that goes 
beyond asking yes/no type questions in relation to core ADHD symptoms: a missed 
diagnosis has potential to jeopardise an individuals’ learning/occupational and social 
relationships, whereas a misdiagnosis could lead to the use of medication which is 
not indicated. History taking should not be reductionist and focus exclusively on 
asking about diagnostic items; a detailed developmental as well as medical history 
and an assessment of family processes and social circumstances (strengths as well as 
weaknesses) are also required. The key steps for assessing children are summarised 
in Figure 1.  
 
It is important to consider whether endorsed symptoms are better explained by 
other difficulties which are amenable to intervention, for example hearing difficulties 
presenting as inattention. However diagnosis is based on clinical phenotype and not 
generally excluded by presumed aetiology. Information should be obtained from 
more than one informant including those who know the individual best at home and 
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at school (or college or work). For deciding who requires referral to a specialist 
assessment service or for monitoring treatment response, it can be helpful to use 
standardised ADHD questionnaires (e.g. Strength and Difficulties Questionnaire,84  
Conners’ Parent and Teacher Rating Scales85) but these are not a substitute for 
detailed history taking prior to diagnosis. Structured interviews are more likely to be 
encountered in a research setting but might be valuable in a clinical context, 
especially ones that do not require extensive, expensive training (e.g. the 
Developmental and Wellbeing Assessment).86 This requires further investigation. 
ADHD symptoms are commonly associated with a range of neurobehavioural 
difficulties.  These could be comorbid features of ADHD but should also be 
considered as differential diagnoses as treatments for these disorders are very 
different. 
 
Mental health symptoms which should also be screened for include those of 
oppositional defiant disorder, conduct disorder, anxiety, and mood disturbance. 
Developmental and learning problems such reading disorders, developmental co-
ordination disorder and tic disorders are also common.87,88,89 Importantly, as ADHD 
and autism spectrum disorder co-occur so frequently,90 autistic symptomatology 
should be considered. ADHD is also associated with lower IQ/intellectual disability91 
and emotion dysregulation symptoms e.g. irritability,92 both of which can further 
complicate the presentation and interpretation of symptoms. In practice, it will be 
rare to find an individual who presents with “uncomplicated” ADHD, even if full 
diagnostic criteria for other comorbid disorders are not met. This makes formalising 
differential diagnoses conceptually difficult, as in reality an individual with 
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neurodevelopmental problems is unlikely to have a “pure” presentation of any one 
condition as a unifying explanation for their difficulties. A formulation should capture 
the full range of developmental, behavioural, and psychiatric difficulties being 
experienced, even if some of these need to be described in terms of sub-threshold 
problems. 
 
Neuropsychological testing does not have role in diagnosis as cognitive processes are 
not a defining characteristic.66 However, it is important to consider cognitive 
comorbidities such as learning disability and dyslexia, which may require specialist 
assessment from education services. 
 
Treatment 
 
There are specific guidelines for the stepwise management of ADHD, including those 
developed by the National Institute for Health and Care Excellence (NICE)7 and the 
Scottish Intercollegiate Guidelines Network (SIGN)93 in the UK, by the Eunethydis 
European ADHD Guidelines Group (EAGG)94 in Europe and by the American Academy 
of Pediatrics (AAP)95 and the American Academy of Child and Adolescent Psychiatry 
(AACAP)96 in the USA. The main difference between them is that US guidance does 
not preclude the use of medication for pre-school children or for those with mild 
ADHD, practice that is not recommended in Europe where a step-wise approach is 
recommended. If medication is prescribed it should be in conjunction with 
behavioural interventions, namely optimised classroom management strategies, 
parental psychoeducation and behavioural management techniques. However, there 
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is no “one size fits all” solution to management. Individual circumstances such as 
current academic or employment demands and medical history should be taken into 
account, and appropriate evidence-based treatments for comorbidities should also 
be initiated.  
 
Non-pharmacological interventions have been extensively investigated over the 
years. The only one of these which currently forms a core part of treatment 
guidelines are behavioural interventions. Initial results from the largest trial to date, 
the multimodal treatment study of children with ADHD (MTA),97 suggested that the 
combination of intensive behavioural treatment plus medication did not offer 
additional benefit over medication alone for core ADHD symptoms, but that the 
combination may have provided some benefit in terms of associated symptoms and 
levels of functioning as well as a lower medication dose being required. A more 
recent series of meta-analyses investigating randomised controlled trials of non-
pharmacological interventions including behavioural interventions concluded that 
they, along with neurofeedback, cognitive training and restricted elimination diets, 
cannot be recommended as interventions for core ADHD symptoms until there is 
better evidence of their effectiveness from blinded assessments.98 Elimination of 
artificial food colouring98 may be beneficial, but to what extent and for whom it may 
be so is unclear.99 A recent meta-analysis has concluded that children with ADHD 
have overall reduced levels of omega-3 and that supplementation improves ADHD 
symptoms to a “modest” degree (an effect size about a quarter as large of that seen 
for pharmacological treatment), but that it is not understood as to whether sub-
normal blood levels should be the indication to treat.100 However, there is blinded 
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evidence of a beneficial effect of behavioural interventions on parenting and child 
conduct problems101 and there is evidence that cognitive behaviour therapy may be 
useful for adults with ADHD when used in conjunction with medication.102 
 
Stimulants such as methylphenidate and dexamfetamine are the first line 
pharmacological treatments for ADHD, and the noradrenaline reuptake inhibitor 
atomoxetine is the second line. Both increase catecholamine availability. There is 
meta-analytic evidence for the efficacy of stimulants for ADHD: in children,103 in 
children with co-occurring autism spectrum disorder,104 and in adults.105 Although it 
is recommended that ADHD is treated in those with autism spectrum disorder 
and/or intellectual disability, medication side effects are more common.106,107 There 
is also meta-analytic evidence for a beneficial effect of atomoxetine in children108 
and in adults.109 Extended-release guanfacine and extended-release clonidine are 
licensed for use in the USA. Atypical antipsychotics are not indicated for treatment of 
core ADHD symptoms.  
 
Pre-treatment checks, including in relation to medical and family medical history (in 
particular cardiac conditions) which are especially important if medication is to be 
initiated, are summarised in Figure 1. Height, weight, blood pressure and pulse 
should be checked at baseline prior to starting medication, and compared to 
normative data. It is reasonable to consider but not mandatory to routinely obtain 
an ECG prior to commencing ADHD medication, and the need to do so should be at 
the treating clinician’s discretion, taking into account factors such as medical history, 
family medical history and physical examination findings.7,110 
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It is best practice to start with a low dose, titrate up according to response, and 
monitor side effects carefully.7 The most common side effects of medications are 
shown in Table 2. There is no evidence that ADHD medication is associated with 
changes in QT interval, sudden cardiac death, acute myocardial infarction and 
stroke.110 Readers are referred to a comprehensive recent review regarding current 
best practice in managing adverse events associated with ADHD medications.110 
Once an optimal response is achieved, height, weight and growth will require regular 
monitoring. NICE guidance recommends that height be measured every six months 
in children and young people, weight be measured three and six months after 
initiation of treatment and every six months thereafter in children, young people and 
adults, and that height and weight in children and young people should be plotted 
on a centile chart.7 Blood pressure and pulse should also be plotted on a centile 
chart before and after each dose change and routinely every 3 months.7 The adverse 
side effects of stimulant medication include appetite suppression and growth 
retardation which can be offset to a degree by stimulant “holidays” on days when 
symptom control is considered less critical such as weekends and holidays, and by 
adjusting the timing of doses. Other side effects of both stimulants and atomoxetine 
include gastrointestinal symptoms, cardiac problems, insomnia and tics (although 
tics are less common with atomoxetine). Stimulants are controlled drugs with 
potential for diversion for abuse, and if there is a concern in this regard then an 
alternative drug may be preferable. 
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Prognosis 
 
Not only do core ADHD symptoms themselves persist, individuals with childhood 
ADHD are also at significant risk of adverse outcomes into adolescence and 
adulthood. In this regard, ADHD behaves dimensionally: there is no distinct threshold 
at which adverse outcomes appear.  A diagnosis of ADHD is associated with low 
academic attainment and premature cessation of education, and poor educational 
outcomes also extend to those with sub-threshold symptoms.111 ADHD also predicts 
serious antisocial behaviour, involvement with the police and substance misuse in 
adolescence.36  
 
Until relatively recently, data on broad outcomes beyond the third decade of life 
were lacking. However, one long term  follow up has shown that it is also associated 
with adverse occupational, economic and social outcomes, antisocial personality 
disorder, and risk of substance use disorders, psychiatric hospitalisations, 
incarcerations and mortality.112 A recent Danish registry-based investigation of 
ADHD113 showed significantly elevated rates of mortality in adult life, mainly as a 
result of accidents, which was especially increased in those with comorbid 
oppositional defiant disorder, conduct disorder and substance misuse.   
 
A recent meta-analysis of ADHD in prison inmates showed on average the 
prevalence of ADHD to be 30.1% in youth prison populations and 26.2% in adult 
populations, with the risk for female prisoners being nearly as high as that for 
24 
 
males.114 Psychiatric comorbidity is high in prisoners with ADHD, especially so for 
adults.115  Although randomised controlled trials of ADHD treatment have reported 
immediate but not as yet longer term benefits, there is epidemiological evidence 
which suggests that medication may reduce criminal behaviour116 and trauma-
related visits to emergency departments.117   
 
Most with ADHD do not develop psychosis or a mood disorder. The largest studies 
only find a small sub-group who additionally develop later schizophrenia or bipolar 
disorder.118,119 Evidence on links with later unipolar depression are mixed112,120 and 
this might be because depression is more common in females who are under-
represented in ADHD samples.  
 
Future research and clinical directions 
 
The early age of onset, male preponderance and strong comorbidity with other 
childhood-onset neurodevelopmental disorders support its inclusion in the DSM-5 
grouping of neurodevelopmental disorders. The previous practice of not diagnosing 
ADHD in the presence of autism spectrum disorder or intellectual disability has been 
a critical barrier to research on aetiological and clinical overlaps and distinctions as 
well as to clinical and educational practice. Unfortunately, referral and treatment 
pathways and service provision in health and education tend to be diagnostically 
focused (i.e. autism only or intellectual disability only) although some clinics and 
services are focusing more broadly on childhood neurodevelopmental disorders, a 
change which is welcomed and supported by research.  
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We accept that for clinical practice, there is a need for strict categories otherwise 
diagnostic spread would become at best unhelpful and at worst risky and unethical 
(for example, use of medication where not indicated) and applying evidence-based 
treatments would become impossible (for example, interpreting the severity of 
difficulties of individuals included in a trial). However, for aetiological and outcome 
research purposes, there is strong evidence in favour of viewing ADHD 
dimensionally.  However, at present, we do not know what sorts of dimensions best 
capture ADHD and at what level they should be measured, for example reported 
symptoms, cognitive tests, brain imaging markers or other biological signatures. 
 
Genetic research is progressing now via large scale collaboration but there is a need 
to understand the clinical as well as biological meaning of findings, if they are to 
impact on our understanding and treatment of ADHD. Currently, there is no 
rationale for routine genetic testing in ADHD because of limited predictive power. 
However, as ADHD is heritable, rates of ADHD in parents of those with ADHD are 
elevated. A pertinent future research question is how might treatment of parent 
ADHD impact on child ADHD features and comorbidity? There is, for example, 
evidence that treating parent depression appears to improve offspring mental 
health.121,122 Another issue for future consideration is that genetic and 
environmental risk factors which “cause” ADHD are not necessarily the same as 
those that alter the later course of the disorder or contribute to adverse outcomes. 
What is greatly needed is research that tests which environmental risks (e.g. social 
and other potentially modifiable risk factors) contribute to and modify the 
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longitudinal course of ADHD across time including better prognosis, using designs 
that can control for unmeasured confounders and genetic contributions from the 
affected person (e.g. twin studies) and related parents (e.g. adoption studies). This 
could inform interventions aimed at optimising outcomes. 
 
So far, medication and behavioural treatments for ADHD have focused on 
symptomatic relief of the core symptoms of inattention, overactivity, and 
impulsivity. However, according to trial-based data, benefits appear to be short-
lived. Another issue is that treatment typically begins after a child has already begun 
to fail across multiple domains. ADHD in many respects behaves like a chronic 
medical disorder. Many features remain problematic long term, although the most 
prominent or presenting features may change with age and development. It creates 
risks of its own and secondary mental health problems commonly arise in mid-
childhood and after puberty. Almost certainly, for many individuals, multi-modal 
interventions that are carefully adjusted over time to prevent complications will be 
required, in the way perhaps that is undertaken for optimising diabetes control.  
How ADHD is best managed across the lifespan and across key transition periods, 
e.g. school entry, comprehensive/high-school entry, transition to adult services and 
transition to parenthood needs much more investigation. Until now, guidelines have 
been based on evidence, but unless research keeps pace, guidance will have to be 
based on professional consensus and that is not very satisfactory for a prevalent, 
impairing condition. 
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Conclusions 
 
ADHD is an extremely important condition due to its high prevalence, persistence 
into adult life and adverse outcomes which extend beyond the affected individual. 
Whilst ADHD is still viewed with scepticism by some and often remains stigmatised 
by the media, the evidence on it being a clinically and biologically meaningful entity 
is robust and consistent across design type and sample. There are established 
assessment methods and good treatment evidence. However, as is true for any 
chronic disorder, repeated assessment is likely to be needed and treatment will 
typically require many adjustments over time. Consideration of impairments beyond 
core diagnostic criteria, developmental change and an individual's psychosocial 
strengths, weaknesses and resources are all important aspects to consider.  
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Table 1. Key diagnostic symptoms of ADHD 
 
Inattentive symptoms Hyperactivity / impulsivity symptoms 
Does not give close attention to details 
or makes careless mistakes 
Fidgets with / taps hands or feet, or 
squirms in seat 
Has difficulty sustaining attention on 
tasks or play activities 
Leaves seat in situations when staying 
seated is expected 
Does not seem to listen when directly 
spoken to  
Runs about or climbs when not 
appropriate (may present as feelings of 
restlessness in adolescents / adults) 
Does not follow through on instructions 
and does not finish schoolwork, chores, 
or duties in the workplace  
Unable to play or undertake leisure 
activities quietly 
Has trouble organising tasks / activities “On the go”, acting as if “driven by a 
motor” 
Avoids, dislikes, or is reluctant to do tasks 
that need sustained mental effort  
Talks excessively 
Loses things needed for tasks / activities  Blurts out answers before a question has 
been finished 
Easily distracted 
 
Has difficulty waiting his/her turn 
Forgetful in daily activities Interrupts or intrudes on others 
 
 
 
Table 2. Some of the more common side effects associated with ADHD medication  
 
 
Side effect MPH ATX 
Loss of appetite    
Growth restriction   
Other gastrointestinal symptoms: abdominal pain, nausea, vomiting, 
diarrhoea (MPH), constipation (ATX), dyspepsia, dry mouth 
  
 
Increase in blood pressure and heart rate   
Cough, nasopharyngitis    
Sleep disturbances   
Tics    
Irritability, mood changes   
Drowsiness   
Dizziness   
Headache   
MPH, methylphenidate. ATX, atomoxetine. 
= common side effect 
 = if a common side effect of both drugs, effect is more pronounced for one compared to the other 
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Figure 1. Origins and trajectories of ADHD 
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Figure 2. Summary of the ADHD clinical assessment process for children 
Obtain detailed clinical history from  
parents / carers and young person 
Carry out core ADHD symptom enquiry:  
Are symptoms out of keeping with child’s age 
and developmental stage? 
Obtain information across settings  
Consider questionnaires as an adjunct 
Screen for associated difficulties  
(e.g. mental health symptoms, other 
neurodevelopmental/learning problems) 
Developmental history (e.g. motor delay)  
Medical history (e.g. epilepsy)  
Family history (e.g. mental health, educational 
history, physical health problems)  
Medical histories especially important in relation 
to cardiac or other risk factors if medication is 
being considered 
Physical assessment:  
Signs of other conditions e.g. dysmorphic 
features, skin lesions 
Motor co-ordination e.g. handwriting, balance 
(To be undertaken more completely if 
considering medication)  
Baseline height, weight, blood pressure, pulse 
Consider severity of symptoms, impact on 
functioning, comorbid symptoms, medical 
history and the family and child’s strengths, 
resources, demands and psychosocial context  
when deciding on treatment options 
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Box 1. Search strategy and selection criteria 
Papers published were first identified by searches of PubMed from 1st January 2010 
to 31st March 2015 using the search terms “ADHD”, “aetiology”, “epidemiology”, 
“prevalence”, “gender”, “time trends”, “prescribing”, “genetic”, “prenatal”, 
“psychosocial”, “toxins”, “institutional rearing”, “longitudinal”, “prognosis”, “animal 
model”, “biological pathway”, “cognition”, “neuroimaging”, “comorbidity”, 
“neuropsychological”, “medication”, “stimulants”, “behavioural interventions”, 
“nonpharmacological interventions”, “diet”, “outcomes”. Only articles published in 
English were included.  Key recent reviews and book chapters were also examined. 
To reduce the number of papers cited the most-up-to-date review papers and meta-
analyses were used where possible. The authors further selected papers according to 
their judgement of the quality of the study or review paper, of the relevance to 
controversial or commonly misunderstood issues and whether findings had clinical 
relevance. Older papers were included when judged to be important. 
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